IT-bolaget Qlosr:s intäkter ökade till 132,2 (125,3) miljoner kronor under det tredje kvartalet 2023...
Following the focusing of the roadmap after the rights issue in October, Nanexa has now announced a ...
FDA has completed the review of Tarpeyo on time. With clear support from the 2-year post-approval st...
Evaxion has a new CEO since September and a new focus on business development.
Norwegian fortsätter använda Qbrick för finansiella videotjänster och rapportering i kombination med...
Edyoutec (”Bolaget”) meddelade fredag den 15 december att Bolaget både signerat ett förvärvsavtal av...
Redeye comments on the news that Nanexa has decided to focus its business on three key areas, which,...
Redeye leaves a comment on Klaria’s announcement of a signed bridge loan agreement with a term of tw...
Eevia Health Plc (publ) (”Eevia Health”, “Eevia” or “the Company”) has entered into a transformation...
Redeye gives its initial comments on yesterday's investor day, which gave a broad overview of the co...
Binero released 9-month figures due to a potential transaction.
Administer issued its second profit warning for 2023, driven mainly by the weakened economic situati...
Redeye updates its view on Energy Save (ES) post its Q2 2023/24 report.
Redeye comments on the private placement worth USD5.
Redeye comments on Annexin’s rights issue's outcome and adjusts our valuation.
Omvärldsläget är tufft men mycket talar för en gynnsam framtid.
Redeye comments on W5’s announcement that Daniel Hopstadius will resign as CEO due to personal reaso...
Redeye comments on the warrants TO2.
Redeye finds that the clinical study of fostrox in liver cancer is progressing favourably with some ...
Redeye comments on Energy Save’s (ES) Q2’23/24 report, showing weaker sales and profitability than e...
